{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:34:17Z","timestamp":1787243657717,"version":"build-2736575974"},"reference-count":65,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,1,28]]},"DOI":"10.18632\/oncotarget.27439","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T10:28:32Z","timestamp":1580207312000},"page":"480-487","source":"Crossref","is-referenced-by-count":52,"title":["Immune system and bone microenvironment: rationale for targeted cancer therapies"],"prefix":"10.18632","volume":"11","author":[{"given":"Gnoni","family":"Antonio","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, \u201cS. Cuore di Ges\u00f9\u201d Hospital, Gallipoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunetti","family":"Oronzo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, National Cancer Research Centre, IRCCS IstitutoTumori \u201cGiovanni Paolo II\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longo","family":"Vito","sequence":"additional","affiliation":[{"name":"Radiology Unit, National Cancer Research Centre, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calabrese","family":"Angela","sequence":"additional","affiliation":[{"name":"Medical ThoracicOncology Unit, IRCCS IstitutoTumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argentiero","family":"Antonel-la","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, National Cancer Research Centre, IRCCS IstitutoTumori \u201cGiovanni Paolo II\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calbi","family":"Roberto","sequence":"additional","affiliation":[{"name":"Radiology Unit, Ente Ecclesiastico \u201cF. Miulli\u201d Hospital, Acquaviva delle Fonti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solimando Antonio","family":"Giovanni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine \u201cG. Baccelli\u201d, University of Bari Medical School, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licchetta","family":"Antonella","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, \u201cS. Cuore di Ges\u00f9\u201d Hospital, Gallipoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/35046196","article-title":"Bone versus immune system","volume":"408","author":"Choi","year":"2000","journal-title":"Nature"},{"key":"2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.abb.2014.08.009","article-title":"The great beauty of osteoclast","volume":"561","author":"Teti","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/720504","article-title":"The Interplay between the bone and the immune system","volume":"720504","author":"Brunetti","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"4","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1002\/art.22175","article-title":"Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system","volume":"54","author":"Teti","year":"2006","journal-title":"Arthritis Rheum"},{"key":"5","doi-asserted-by":"publisher","first-page":"e40044","DOI":"10.1371\/journal.pone.0040044","article-title":"T-lymphocytes enable osteoblast maturation via IL-17F during early phase of fracture repair","volume":"7","author":"Alman","year":"2012","journal-title":"PLoS One"},{"key":"6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/14712598.2017.1315405","article-title":"Immunotherapy for colorectal cancer: where are we heading?","volume":"17","author":"Russano","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10753-013-9782-0","article-title":"Effect of IL-15 and natural killer cells on osteoclasts and osteoblasts in a mouse coculture","volume":"37","author":"Noguchi","year":"2014","journal-title":"Inflammation"},{"key":"8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/stem.1040","article-title":"Induction of osteogenesis in mesenchymal stem cells by activated monocytes\/macrophages depends on oncostatin M signaling","volume":"30","author":"Blanchard","year":"2012","journal-title":"Stem Cells"},{"key":"9","doi-asserted-by":"publisher","first-page":"e74402","DOI":"10.1371\/journal.pone.0074402","article-title":"Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey","volume":"8","author":"Catalano","year":"2013","journal-title":"PLoS One"},{"key":"10","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1182\/blood-2006-08-041384","article-title":"Osteoblasts support Blymphocyte commitment and differentiation from hematopoietic stem cells","volume":"109","author":"Emerson","year":"2007","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.20020784","article-title":"The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7","volume":"196","author":"Allman","year":"2002","journal-title":"J Exp Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/aja.1001720204","article-title":"Morphological evidence of reduced bone resorption in the osteosclerotic (oc) mouse","volume":"172","author":"Marks","year":"1985","journal-title":"Am J Anat"},{"key":"13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.20110994","article-title":"Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow","volume":"209","author":"Blin-Wakkach","year":"2012","journal-title":"J Exp Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1172\/JCI26132","article-title":"MCSF mediates TNF-induced inflammatory osteolysis","volume":"115","author":"Teitelbaum","year":"2005","journal-title":"J Clin Invest"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.04.013","article-title":"Secreted osteoclastogenic factor of activated T cells (SOFAT), a novel osteoclast activator, in chronic periodontitis","volume":"74","author":"Napimoga","year":"2013","journal-title":"Hum Immunol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood.V96.5.1873","article-title":"Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines","volume":"96","author":"Pacifici","year":"2000","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4110\/in.2018.18.e8","article-title":"Regulation of osteoclast differentiation by cytokine networks","volume":"18","author":"Rho","year":"2018","journal-title":"Immune Netw"},{"key":"18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S8756-3282(02)00915-8","article-title":"Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism","volume":"32","author":"Athanasou","year":"2003","journal-title":"Bone"},{"key":"19","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1002\/eji.200838192","article-title":"IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells","volume":"38","author":"Aeschlimann","year":"2008","journal-title":"Eur J Immunol"},{"key":"20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/joca.1998.0230","article-title":"Prostaglandins and bone: physiology and pathophysiology","volume":"7","author":"Raisz","year":"1999","journal-title":"Osteoarthritis Cartilage"},{"key":"21","doi-asserted-by":"publisher","first-page":"R246","DOI":"10.1186\/ar4089","article-title":"IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis","volume":"14","author":"Cho","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"22","doi-asserted-by":"publisher","first-page":"11535","DOI":"10.1074\/jbc.M607999200","article-title":"Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways","volume":"283","author":"Ebisu","year":"2008","journal-title":"J Biol Chem"},{"key":"23","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1158\/1078-0432.CCR-10-1499","article-title":"Stem cell quiescence","volume":"17","author":"Bhatia","year":"2011","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q","article-title":"Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients","volume":"92","author":"Schirrmacher","year":"2001","journal-title":"Int J Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s13402-018-0373-9","article-title":"Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications","volume":"41","author":"Voutsadakis","year":"2018","journal-title":"Cell Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/0008-5472.CAN-17-1891","article-title":"NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell lines","volume":"78","author":"Marconi","year":"2018","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11914-007-0024-y","article-title":"The RANKL\/RANK\/OPG pathway","volume":"5","author":"Xing","year":"2007","journal-title":"Curr Osteoporos Rep"},{"key":"28","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1182\/blood-2004-09-3662","article-title":"A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation","volume":"106","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1172\/JCI11089","article-title":"Interactions between immune and bone cells: new insights with many remaining questions","volume":"106","author":"Lorenzo","year":"2000","journal-title":"J Clin Invest"},{"key":"31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Penninger","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Scadden","year":"2003","journal-title":"Nature"},{"key":"33","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/nm1518","article-title":"Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells","volume":"12","author":"Beissert","year":"2006","journal-title":"Nat Med"},{"key":"34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"35","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood-2013-07-517219","article-title":"Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts","volume":"124","author":"Teruya-Feldstein","year":"2014","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-011-0974-x","article-title":"Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications","volume":"60","author":"Dimopoulos","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"37","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Smyth","year":"2011","journal-title":"Science"},{"key":"38","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat Med"},{"key":"39","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Kostenuik","year":"2001","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Dougall","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Schreiber","year":"2006","journal-title":"Nature"},{"key":"42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5173\/ceju.2011.04.art2","article-title":"Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review","volume":"64","author":"Tenaglia","year":"2011","journal-title":"Cent European J Urol"},{"key":"43","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3390\/ijms20102587","article-title":"Prostate Cancer and Bone Metastases: The Underlying Mechanisms","volume":"20","author":"Ima-Nirwana","year":"2019","journal-title":"Int J Mol Sci"},{"key":"44","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","article-title":"T cells support osteoclastogenesis in anmodel derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction","volume":"104","author":"Grano","year":"2004","journal-title":"Blood"},{"key":"45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin driven mammary cancer","volume":"468","author":"Ormandy","year":"2010","journal-title":"Nature"},{"key":"46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/187152012799014977","article-title":"Potential anticancer properties of bisphosphonates: insights from preclinical studies","volume":"12","author":"Clezardin","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"48","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Seaman","year":"2003","journal-title":"Cancer"},{"key":"49","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-13-2275","article-title":"Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed treatment meta-analysis","volume":"19","author":"Brown","year":"2013","journal-title":"Clin Cancer Res"},{"key":"50","doi-asserted-by":"publisher","first-page":"625060","DOI":"10.1155\/2014\/625060","article-title":"The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis","volume":"2014","author":"Sen","year":"2014","journal-title":"J Oncol"},{"key":"51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12885-019-5379-9","article-title":"Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells","volume":"19","author":"Lin","year":"2019","journal-title":"BMC Cancer"},{"key":"52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis","volume":"18","author":"Mauri","year":"2013","journal-title":"Oncologist"},{"key":"53","doi-asserted-by":"publisher","first-page":"e83026","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Carteni","year":"2013","journal-title":"PLoS One"},{"key":"54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13046-015-0122-0","article-title":"Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?","volume":"34","author":"Ortega","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"55","doi-asserted-by":"publisher","first-page":"67142","DOI":"10.18632\/oncotarget.11565","article-title":"Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib","volume":"7","author":"Frassineti","year":"2016","journal-title":"Oncotarget"},{"key":"56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1749-6632.2012.06674.x","article-title":"The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction","volume":"1263","author":"Wagman","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14712598.2013.843667","article-title":"Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor","volume":"14","author":"Silvestris","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Zhou","year":"2016","journal-title":"Eur J Cancer"},{"key":"59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Kueppers","year":"2016","journal-title":"Support Care Cancer"},{"key":"60","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.jbo.2019.100252","article-title":"Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials","volume":"18","author":"Latteri","year":"2019","journal-title":"J Bone Oncol"},{"key":"61","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/bcp.13852","article-title":"Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss","volume":"85","author":"Costa","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"62","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.critrevonc.2017.09.008","article-title":"The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials","volume":"120","author":"Santini","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"63","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.21873\/anticanres.11744","article-title":"Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy","volume":"37","author":"Trodella","year":"2017","journal-title":"Anticancer Res"},{"key":"64","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Seaman","year":"2004","journal-title":"Cancer"},{"key":"65","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing\u2019s sarcoma patients","volume":"70","author":"Redini","year":"2010","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T11:45:13Z","timestamp":1591443913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,1,28]]}},"alternative-id":["27439","32064051"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27439","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]}}}